Current European Claim legislation does not allow health claims for this substance (yet)
See the complete Disclosure in the Risks and Disclosures section of To view or add a comment, sign in Priovant Therapeutics Scores Another Win as Brepocitinib Delivers Breakthrough Phase 2 Data in Cutaneous Sarcoidosis Momentum is clearly building behind brepocitinib, the TYK2/JAK1 inhibitor developed by Priovant Therapeutics, the autoimmune-focused biotech created by Pfizer and @Roivant Sciences
Re-engage With Your Group Life gets busy, but support is still here
Survey respondents who were aware of GLP - 1 drugs yet were not using them cited reasons such as the high cost (treatments currently cost over $1,000 per month), limited insurance coverage, required weekly injections for sustained results and concerns about side effects such as nausea
Perfect Aminos essential amino acids in the morning and post-workout
Ashkar H et al (2024): Dobutamine